Chinese Red Tiger Plaster

Description

The product is identified by the SPL code 34089-3. No additional specific description details are provided in the available data.

Uses and Indications

This drug is indicated for the temporary relief of muscle soreness and minor joint pain associated with sprains, backache, and strains.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Healthcare professionals are advised to follow the outlined procedure for the application of the patch.

Prior to application, the affected area should be cleaned and dried thoroughly. A patch should be removed from its packaging, ensuring that it is handled with care. The protective film should be partially peeled back, allowing the exposed part of the patch to be applied directly to the site of pain.

Once the patch is positioned correctly, the remaining protective film should be carefully removed while simultaneously pressing the patch firmly against the skin to ensure proper adhesion.

The patch should be left in place for a maximum duration of 8 hours.

Packaging & NDC

Below are the non-prescription pack sizes of Chinese Red Tiger Plaster (menthol). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

Pregnant patients should be aware that the safety of this medication during pregnancy has not been established. There are no available data regarding the potential risks or fetal outcomes associated with the use of this medication in pregnant individuals. Healthcare professionals are advised to consider the lack of information when prescribing this medication to women of childbearing potential and to discuss the potential risks and benefits with their patients. It is recommended that healthcare providers remain vigilant and informed about any emerging data related to the use of this medication in pregnant patients.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or its effects during lactation. Healthcare professionals should consider the lack of data when advising lactating mothers about the use of this medication. It is recommended to monitor breastfed infants for any potential adverse effects if the medication is administered to a nursing mother.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the context of overdosage, there is currently no specific information available regarding the effects or management of an overdose for this medication. Healthcare professionals are advised to monitor patients closely for any unusual symptoms or adverse reactions that may arise.

In the absence of detailed overdosage data, it is recommended that standard supportive care measures be implemented. This may include symptomatic treatment and monitoring of vital signs. If an overdose is suspected, healthcare providers should consider contacting a poison control center or seeking guidance from a medical toxicologist for further management strategies.

As always, maintaining a thorough understanding of the patient's medical history and current medications is essential in managing any potential overdosage scenarios effectively.

Nonclinical Toxicology

There is currently no available data regarding teratogenic or non-teratogenic effects associated with the substance. Additionally, no relevant information has been identified in the context of nonclinical toxicology, animal pharmacology, or toxicology studies. As such, the assessment of these parameters remains unaddressed in the existing literature.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact the Poison Control Center if the product is accidentally swallowed. It is important to instruct patients not to apply the product to wounds or damaged skin, as this may lead to adverse effects.

Patients should be informed that the product should not be used in conjunction with other ointments, creams, sprays, or liniments, as this could result in unwanted interactions. Additionally, they should be cautioned against bandaging the area or using heating pads or devices while using the product, as this may exacerbate side effects.

Storage instructions should be clearly communicated; patients should keep the product in a cool, dry place, away from direct sunlight to maintain its efficacy.

Patients must be made aware that if they experience swelling, blistering, or any other discomfort, they should discontinue use immediately and consult their doctor. Furthermore, if symptoms persist after using the product for more than 7 days, they should stop using it and seek medical advice.

When using the product, patients should be reminded to follow the directions carefully and to avoid contact with the eyes or mucous membranes to prevent irritation or injury.

Storage and Handling

The product is supplied in a configuration that includes specific NDC numbers, which are essential for identification and inventory management. It is crucial to store the product in a cool, dry place, ensuring that it is kept away from direct sunlight to maintain its integrity and effectiveness. Proper storage conditions are vital for preserving the quality of the product throughout its shelf life.

Additional Clinical Information

Patients should ensure the affected area is clean and dry before applying the patch. To administer, they should remove the patch from its packaging, partially peel back the protective film, and apply the exposed part to the site of pain. The remaining film should be carefully removed while pressing the patch firmly onto the skin, which can remain in place for up to 8 hours.

Clinicians should advise patients to seek medical assistance or contact the Poison Control Center immediately if the patch is accidentally swallowed. No further information is available regarding laboratory tests, abuse potential, or postmarketing experiences.

Drug Information (PDF)

This file contains official product information for Chinese Red Tiger Plaster, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)